This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the standard of care and the potential of XEN1101 as part of treatment for MDD

Ticker(s): XENE

Who's the expert?

Institution: Columbia Psychiatric Associates (Private Practice)

  • Psychiatrist in private practice in Columbia, South Carolina who manages 250 patients with major depressive disorder and 100 patients with Bipolar Depression.
  • Specializes in outpatient depressive and anxiety disorders for adults over the age of 23.
  • Familiar with the published literature for lumateperone in treating bipolar depression.

Interview Goal
The goal of this interview is to discuss the standard of care and the potential of  XEN1101  as part of treatment for MDD  in light of the Phase 2 clinical trial initiation  by Xenon Pharmaceuticals

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.